Prevention of dextran-induced anaphylactic reactions by hapten inhibition. II. A comparison of the effects of 20 ml dextran 1, 15%, administered either admixed to or before dextran 70 or dextran 40.
The incidence of dextran-induced anaphylactoid/anaphylactic reactions (DIAR) was investigated after hapten inhibition employing two different modes of administration of dextran 1 (Mw 1 000 dalton). The trial was carried out as an open prospective study that comprised 12 060 patients. They were randomized into two groups--one receiving a mixture of 20 ml dextran 1, 15%, (Promiten) and 500 ml dextran 70 (Macrodex) or dextran 40 (Rheomacrodex) (admixture group), the other receiving an intravenous injection of 20 ml dextran 1, 15% before the infusion of dextran 70 or 40 (preinjection group). DIAR were graded according to severity from I to V. In the admixture group eight DIAR of grade II, one of grade IV and one of grade V were observed, while in the preinjection group two DIAR of grade II occurred. The admixture of dextran 1 to dextran 70 or 40 does not prevent the occurrence of severe DIAR in the dose investigated.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000276:immunology / Q000517:prevention & control*; D000936:Antigen-Antibody Complex; D001667:Binding, Competitive; D002648:Child; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D005260:Female; D006241:Haptens / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011446:Prospective Studies
D000936:Antigen-Antibody Complex; D003911:Dextrans; D006241:Haptens